Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 15, 2022
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
[ Tue, Mar 15th 2022
] - WOPRAI
Mon, March 14, 2022
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
[ Mon, Mar 14th 2022
] - WOPRAI
Sumant Kulkarni Maintained (CARA) at Strong Buy with Decreased Target to $29 on, Mar 14th, 2022
Sumant Kulkarni of Canaccord Genuity, Maintained "Cara Therapeutics, Inc." (CARA) at Strong Buy with Decreased Target from $33 to $29 on, Mar 14th, 2022.
Sumant has made no other calls on CARA in the last 4 months.
There is 1 other peer that has a rating on CARA. Out of the 1 peers that are also analyzing CARA, 0 agree with Sumant's Rating of Hold.
This is the rating of the analyst that currently disagrees with Sumant
- Jessica Fye of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $20 on, Tuesday, March 8th, 2022
